De novo malignancies are a current problem in patients with organ transplantation.
The incidence is higher as a result of increases of oncogenic viruses in immunosuppressed organ recipients.
Reports have shown increased incidence of de novo tumors such as malignant lymphomas and cutaneous neoplasms, but decreased incidence of breast cancer.
|83% of all patients were diagnosed at an early stages|
A variety of factors affect de novo breast cancer development in organ recipients, including immunosuppression, viruses, and underlying disease.
In this study, doctors from the University of Pittsburgh evaluated the incidence and management of patients with de novo breast cancer. They also evaluated the age-adjusted incidence of de novo breast cancer in published reports.
According to age-adjusted rates presented by the National Cancer Institute's Surveillance, Epidemiology and End Results data, the team found an increased incidence rate of de novo breast cancer in the published series.
The team's incidence rate of de novo breast cancer was determined in a similar way to the Surveillance, Epidemiology and End Results data.
They determined that 83% of all patients were diagnosed at early stages.
They also found that it appeared to take longer for de novo breast cancer to develop in patients treated with tacrolimus than in patients treated with cyclosporine.
Dr Tahir Oruc's team concluded, "Surgical treatment of breast cancer in liver recipients is the same as treatment of breast cancer in patients without transplantation".
"However, the effects of chemotherapy, radiotherapy, and/or tamoxifen remain unclear in transplanted patients and need to be evaluated in larger studies".